(38 intermediate revisions by 3 users not shown) | |||
Line 6: | Line 6: | ||
<script src="https://ajax.googleapis.com/ajax/libs/jquery/3.1.0/jquery.min.js"></script> | <script src="https://ajax.googleapis.com/ajax/libs/jquery/3.1.0/jquery.min.js"></script> | ||
<link href="https://2016.igem.org/Team:NCTU_Formosa/wiki_reset?action=raw&ctype=text/css" rel="stylesheet"> | <link href="https://2016.igem.org/Team:NCTU_Formosa/wiki_reset?action=raw&ctype=text/css" rel="stylesheet"> | ||
− | <link href="https://fonts.googleapis.com/css?family=Open+Sans:300" rel="stylesheet"> | + | <link href="https://fonts.googleapis.com/css?family=Open+Sans:300,400" rel="stylesheet"> |
Line 30: | Line 30: | ||
border: 0; | border: 0; | ||
outline: 0; | outline: 0; | ||
− | + | vertical-align: baseline; | |
+ | background: transparent; | ||
} | } | ||
− | + | p{ | |
− | + | ||
font-family: 'Open Sans', sans-serif; | font-family: 'Open Sans', sans-serif; | ||
font-weight: 300; | font-weight: 300; | ||
Line 41: | Line 41: | ||
background-color:rgb(51,51,51) !important; | background-color:rgb(51,51,51) !important; | ||
line-height:1; | line-height:1; | ||
+ | } | ||
+ | |||
+ | table { | ||
+ | border-collapse: collapse; | ||
+ | border-spacing: 0; | ||
} | } | ||
/*大圖*/ | /*大圖*/ | ||
Line 77: | Line 82: | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
/*content*/ | /*content*/ | ||
.content_container{ | .content_container{ | ||
position:relative; | position:relative; | ||
− | left: | + | left:5vw; |
− | right: | + | right:5vw; |
margin:0 auto; | margin:0 auto; | ||
width:60vw; | width:60vw; | ||
height:auto; | height:auto; | ||
+ | |||
} | } | ||
.title{ | .title{ | ||
font-size:25pt !important; | font-size:25pt !important; | ||
text-shadow:1px 1px 10px rgb(0, 206, 255); | text-shadow:1px 1px 10px rgb(0, 206, 255); | ||
+ | border-left:3px solid rgb(0, 206, 255); | ||
padding-left:10px !important; | padding-left:10px !important; | ||
color:rgb(0, 206, 255); | color:rgb(0, 206, 255); | ||
margin-top:20px; | margin-top:20px; | ||
margin-bottom:10px; | margin-bottom:10px; | ||
− | |||
} | } | ||
.content{ | .content{ | ||
Line 258: | Line 106: | ||
text-indent:2em; | text-indent:2em; | ||
color:#F3F7F7; | color:#F3F7F7; | ||
− | |||
padding-top:15px; | padding-top:15px; | ||
padding-bottom:15px; | padding-bottom:15px; | ||
Line 275: | Line 122: | ||
color:#F3F7F7 !important; | color:#F3F7F7 !important; | ||
font-size:11pt !important; | font-size:11pt !important; | ||
− | padding-top: | + | padding-top:5px; |
− | padding-bottom: | + | padding-bottom:20px; |
width:50vw; | width:50vw; | ||
margin:auto; | margin:auto; | ||
Line 314: | Line 161: | ||
margin: auto; | margin: auto; | ||
} | } | ||
− | |||
− | |||
− | |||
.img-position{ | .img-position{ | ||
Line 341: | Line 185: | ||
} | } | ||
+ | #groupparts{ | ||
+ | margin-left:26vw; | ||
+ | } | ||
</style> | </style> | ||
</head> | </head> | ||
Line 347: | Line 194: | ||
<!--圖片--> | <!--圖片--> | ||
<div class="img-container"> | <div class="img-container"> | ||
− | <img src="https://static.igem.org/mediawiki/2016/ | + | <img src="https://static.igem.org/mediawiki/2016/7/75/NCTU_PARTS_BIG_PICTURE.png" class="main-img" width="100%"> |
</div> | </div> | ||
<!------------wiki content-------------> | <!------------wiki content-------------> | ||
− | |||
<section class="content_container"> | <section class="content_container"> | ||
Line 358: | Line 204: | ||
<p class="title">Biobrick design<p> | <p class="title">Biobrick design<p> | ||
− | <p class="content">Our goal is to produce a new bio-repellent of insects, | + | <p class="content">Our goal is to produce a new bio-repellent of insects, PANTIDE, which is successfully an alternative for chemical pesticide. We strive to express PANTIDE that can be used to reduce appetite of the major pests in the farmland. So far, we have already designed two types of BioBricks that three spider toxic peptides are included with and without lectin respectively. We can then do several experiments to test the function of BioBricks and prove that PANTIDE truly works.</p> |
− | <p class="content">We submitted a collection of spider toxins | + | <p class="content">We submitted a collection of spider toxins, lectin, and GS linker as basic parts, and the composite parts with T7 promoter and RBS. All in all we have provided twelve new BioBricks to the Registry in total this year. All BioBricks were sequence-confirmed. Our parts are presented in table view at our Registry summary page.(table 1)</p> |
</div> | </div> | ||
</section> | </section> | ||
Line 366: | Line 212: | ||
</html> | </html> | ||
− | <groupparts> | + | <groupparts>iGEM2016 NCTU_Formosa</groupparts> |
+ | <p class="content-image" style="text-align:center !important;">Table 1. Registry of Standard Biological Parts</p> | ||
<html> | <html> | ||
− | + | <section class="content_container"> | |
− | + | <div> | |
− | + | ||
− | <section class="content_container"> | + | |
− | <div> | + | |
− | + | ||
− | + | ||
− | + | ||
<p class="content">* Note: The relevant literature information for each part, including their full characterization data can be found at their respective pages in the Registry of Standard Biological Parts.</p> | <p class="content">* Note: The relevant literature information for each part, including their full characterization data can be found at their respective pages in the Registry of Standard Biological Parts.</p> | ||
− | <p class="content">* Note: In the composite parts, each of our toxic peptides contains a hexahistidine tag-coding sequence fused at its downstream to facilitate | + | <p class="content">* Note: In the composite parts, each of our toxic peptides contains a hexahistidine tag-coding sequence fused at its downstream to facilitate PANTIDE detection and purification.</p> |
</div> | </div> | ||
Latest revision as of 13:31, 14 November 2016
Biobrick design
Our goal is to produce a new bio-repellent of insects, PANTIDE, which is successfully an alternative for chemical pesticide. We strive to express PANTIDE that can be used to reduce appetite of the major pests in the farmland. So far, we have already designed two types of BioBricks that three spider toxic peptides are included with and without lectin respectively. We can then do several experiments to test the function of BioBricks and prove that PANTIDE truly works.
We submitted a collection of spider toxins, lectin, and GS linker as basic parts, and the composite parts with T7 promoter and RBS. All in all we have provided twelve new BioBricks to the Registry in total this year. All BioBricks were sequence-confirmed. Our parts are presented in table view at our Registry summary page.(table 1)
<groupparts>iGEM2016 NCTU_Formosa</groupparts>
Table 1. Registry of Standard Biological Parts
* Note: The relevant literature information for each part, including their full characterization data can be found at their respective pages in the Registry of Standard Biological Parts. * Note: In the composite parts, each of our toxic peptides contains a hexahistidine tag-coding sequence fused at its downstream to facilitate PANTIDE detection and purification.